#1 Clinical Trials Search in Europe

Mercaptopurine

Mercaptopurine, also known as 6-MP, is a medication being studied in various clinical trials for its potential in treating different conditions, primarily cancers like leukemia and glioblastoma, as well as autoimmune diseases such as Crohn’s disease. These trials aim to evaluate the drug’s effectiveness, safety, and optimal dosing strategies across different patient populations and in combination with other treatments.

Table of Contents

What is Mercaptopurine?

Mercaptopurine, also known as 6-mercaptopurine (6-MP), is an important medication used in the treatment of various conditions, primarily certain types of cancer and inflammatory bowel diseases. It belongs to a class of drugs called antimetabolites, which work by interfering with the growth of certain cells in the body[1]. Some common brand names for mercaptopurine include Purinethol[2] and Xaluprine[1].

What Conditions Does Mercaptopurine Treat?

Mercaptopurine is used to treat several medical conditions, including:

  • Acute Lymphoblastic Leukemia (ALL): This is a type of cancer that affects the white blood cells. Mercaptopurine plays a crucial role in the maintenance phase of ALL treatment, especially in children and young adults[3][4].
  • Crohn’s Disease: This is a type of inflammatory bowel disease. Mercaptopurine is used to reduce inflammation and maintain remission in patients with Crohn’s disease[5].
  • Glioblastoma: Some research is exploring the use of mercaptopurine in combination with other drugs for treating this aggressive type of brain cancer[6].

How Does Mercaptopurine Work?

Mercaptopurine works by interfering with the production of DNA in cells. Specifically, it:

  • Prevents cells from making and repairing DNA, which is essential for cell division and growth.
  • Affects rapidly dividing cells, such as cancer cells, more than normal cells.
  • In inflammatory conditions like Crohn’s disease, it helps to suppress the overactive immune system[5].

In some cases, mercaptopurine is used in combination with other drugs. For example, in the treatment of acute lymphoblastic leukemia, it may be used alongside drugs like methotrexate, vincristine, and asparaginase[3].

How is Mercaptopurine Administered?

Mercaptopurine is typically administered orally (by mouth). It comes in different forms:

  • Tablets: The most common form, usually available as 50 mg tablets[2].
  • Oral suspension: A liquid form that can be easier for some patients to take, especially children[1].
  • Delayed-release tablets: A newer formulation being researched for targeted delivery to specific parts of the intestine, which may be beneficial for patients with Crohn’s disease[7].

Dosage Information

The dosage of mercaptopurine can vary depending on the condition being treated, the patient’s body weight, and other factors. Some general guidelines include:

  • For acute lymphoblastic leukemia in children: Typically 1.5 to 2.5 mg per kg of body weight per day[3].
  • For Crohn’s disease: Often started at 1-1.5 mg per kg of body weight per day, with adjustments made based on response and side effects[5].
  • In some research studies, fixed doses of 40 mg or 80 mg are being explored for specific formulations[7].

It’s crucial to take mercaptopurine exactly as prescribed by your doctor. The dose may need to be adjusted based on your response to the medication and any side effects you experience.

Potential Side Effects

Like all medications, mercaptopurine can cause side effects. Some of the potential side effects include:

  • Bone marrow suppression: This can lead to a decrease in white blood cells (increasing the risk of infections), red blood cells (potentially causing anemia), and platelets (which can increase the risk of bleeding)[7].
  • Liver toxicity: Regular blood tests are usually done to monitor liver function.
  • Nausea and vomiting
  • Pancreatitis: Inflammation of the pancreas, which can be serious.
  • Increased risk of certain cancers: Long-term use may slightly increase the risk of certain types of cancer.

Your doctor will monitor you closely for these side effects and may adjust your dose or prescribe additional medications to manage them.

Ongoing Research and Future Prospects

Researchers are continually working to improve the use of mercaptopurine and explore new applications. Some areas of ongoing research include:

  • Delayed-release formulations: These are being studied for targeted delivery in Crohn’s disease, potentially allowing for lower doses and fewer side effects[7].
  • Combination therapies: Researchers are exploring how mercaptopurine works in combination with other drugs, such as in the treatment of glioblastoma[6].
  • Personalized dosing: Studies are looking at genetic factors that influence how individuals respond to mercaptopurine, which could lead to more personalized treatment approaches[8].

These ongoing studies aim to improve the effectiveness of mercaptopurine while minimizing its side effects, potentially expanding its use in treating various conditions.

Aspect Details
Primary Conditions Studied Acute Lymphoblastic Leukemia, Glioblastoma, Crohn’s Disease, Breast and Ovarian Cancers
Administration Methods Oral tablets, Liquid formulations, Delayed-release formulations
Dosage Ranges 25-75 mg/m²/day, with variations based on specific trials and conditions
Common Combinations Methotrexate, PEG-asparaginase, Temozolomide
Key Outcome Measures Clinical response rates, Progression-free survival, Overall survival, Pharmacokinetic parameters
Safety Monitoring Regular blood tests, Liver function tests, Monitoring for myelosuppression
Special Research Areas Genetic factors influencing response, Targeted delivery methods, Reducing systemic side effects
Trial Durations Single-dose studies to long-term maintenance therapy (up to several years)

FAQ

  • What is Mercaptopurine used for in clinical trials? Mercaptopurine is being studied for various conditions, including acute lymphoblastic leukemia, glioblastoma, Crohn's disease, and certain types of breast and ovarian cancers. It's often used in combination with other drugs to enhance treatment effectiveness.
  • How is Mercaptopurine administered in these trials? Mercaptopurine is typically administered orally, either as tablets or in liquid form. The dosage and frequency can vary depending on the specific trial and condition being treated. Some trials are exploring delayed-release formulations for targeted delivery to specific areas of the body.
  • What are the potential side effects of Mercaptopurine? Common side effects can include myelosuppression (decreased blood cell production), liver toxicity, and gastrointestinal issues. Some trials are specifically looking at ways to reduce these side effects, such as using lower doses or targeted delivery methods.
  • How long do patients typically take Mercaptopurine in these trials? The duration of treatment varies widely depending on the trial and condition. Some studies involve single doses for pharmacokinetic analysis, while others may continue treatment for several months or even years, especially in cancer maintenance therapy.
  • Are there any special considerations for patients taking Mercaptopurine? Yes, patients taking Mercaptopurine often require regular blood tests to monitor for potential side effects. Some trials are also exploring genetic factors that may influence how patients respond to the drug, which could help in personalizing treatment approaches.

Ongoing Clinical Trials on Mercaptopurine

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • Study of Inotuzumab Ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland Germany +8

  • Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +13

  • Study on Hydroxyurea and Valproic Acid or 6-Mercaptopurine with Valproic Acid for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland France Germany +8

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

Glossary

  • 6-MP: An abbreviation for 6-mercaptopurine, the active ingredient in Mercaptopurine medications.
  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects white blood cells called lymphocytes. It's one of the primary conditions for which Mercaptopurine is being studied.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord, which is being targeted in some Mercaptopurine trials.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, which is being studied as a potential target for Mercaptopurine treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioequivalence: The property of two drug products having the same biological effect and availability in the body.
  • CDAI: Crohn's Disease Activity Index, a measure used to quantify the symptoms of Crohn's disease.
  • Myelosuppression: A condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets.
  • BRCA mutation: A genetic mutation that increases the risk of breast and ovarian cancers, which is being studied in relation to Mercaptopurine treatment.
  • Delayed Release: A drug formulation designed to release the active ingredient at a specific time or location in the body, often used to target specific areas of the digestive tract.

References

  1. https://clinicaltrials.gov/study/NCT01697020
  2. https://clinicaltrials.gov/study/NCT00648336
  3. https://clinicaltrials.gov/study/NCT00176462
  4. https://clinicaltrials.gov/study/NCT00548431
  5. https://clinicaltrials.gov/study/NCT02177071
  6. https://clinicaltrials.gov/study/NCT06279767
  7. https://clinicaltrials.gov/study/NCT01094613
  8. https://clinicaltrials.gov/study/NCT03920813